Literature DB >> 16394286

Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.

A Quintero1, J Alvarez-Kindelan, R J Luque, R Gonzalez-Campora, M J Requena, R Montironi, A Lopez-Beltran.   

Abstract

AIMS: To evaluate whether ki-67 labelling index (LI) has independent prognostic value for survival of patients with bladder urothelial tumours graded according to the 2004 World Health Organisation classification.
METHODS: Ki-67 LI was evaluated in 164 cases using the grid counting method. Non-invasive (stage Ta) tumours were: papilloma (n = 5), papillary urothelial neoplasia of low malignant potential (PUNLMP; n = 26), and low (LG; n = 34) or high grade (HG; n = 15) papillary urothelial carcinoma. Early invasive (stage T1) tumours were: LG (n = 58) and HG (n = 26) carcinoma. Statistical analysis included Fisher and chi2 tests, and mean comparisons by ANOVA and t test. Univariate and multivariate survival analyses were performed according to the Kaplan-Meier method with log rank test and Cox's proportional hazard method.
RESULTS: Mean ki-67 LI increased from papilloma to PUNLMP, LG, and HG in stage Ta (p<0.0001) and from LG to HG in stage T1 (p = 0.013) tumours. High tumour proliferation (>13%) was related to greater tumour size (p = 0.036), recurrence (p = 0.036), progression (p = 0.035), survival (p = 0.054), and high p53 accumulation (p = 0.015). Ki-67 LI and tumour size were independent predictors of disease free survival (DFS), but only ki-67 LI was related to progression free survival (PFS). Cancer specific overall survival (OS) was related to ki-67 LI, tumour size, and p27kip1 downregulation. Ki-67 LI was the main independent predictor of DFS (p = 0.0005), PFS (p = 0.0162), and cancer specific OS (p = 00195).
CONCLUSION: Tumour proliferation measured by Ki-67 LI is related to tumour recurrence, stage progression, and is an independent predictor of DFS, PFS, and cancer specific OS in TaT1 bladder urothelial cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394286      PMCID: PMC1860249          DOI: 10.1136/jcp.2004.022939

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

Review 1.  P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.

Authors:  J W Slaton; W F Benedict; C P Dinney
Journal:  Urology       Date:  2001-05       Impact factor: 2.649

2.  Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.

Authors:  Marco G Bol; Jan P Baak; Susanne Buhr-Wildhagen; Arnold-Jan Kruse; Kjell H Kjellevold; Emiel A Janssen; Oddvar Mestad; Per Øgreid
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

3.  Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia.

Authors:  S J Cina; K J Lancaster-Weiss; K Lecksell; J I Epstein
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

4.  Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group.

Authors:  T Liukkonen; P Lipponen; M Raitanen; E Kaasinen; M Ala-Opas; P Rajala; V M Kosma
Journal:  Urol Res       Date:  2000-10

5.  MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors.

Authors:  J W Oosterhuis; R F Schapers; M L Janssen-Heijnen; A W Smeets; R P Pauwels
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

Review 6.  Molecular pathology of non-invasive urothelial carcinomas (part I).

Authors:  Burkhard Helpap; Bernd J Schmitz-Dräger; Peter W Hamilton; Giovanni Muzzonigro; Andrea B Galosi; Karl H Kurth; David Lubaroff; David J Waters; Michael J Droller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

7.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

Authors:  A R Zlotta; J C Noel; I Fayt; A Drowart; J P Van Vooren; K Huygen; J Simon; C C Schulman
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

8.  Frequent FGFR3 mutations in urothelial papilloma.

Authors:  Bas W G van Rhijn; Rodolfo Montironi; Ellen C Zwarthoff; Adriaan C Jöbsis; Theo H van der Kwast
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

9.  Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.

Authors:  Achille Pich; Luigi Chiusa; Andrea Formiconi; Diego Galliano; Paola Bortolin; Alberto Comino; Roberto Navone
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

10.  Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors.

Authors:  Yan Yan; Gerald L Andriole; Peter A Humphrey; Adam S Kibel
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

View more
  24 in total

1.  Divergent squamous differentiation in upper urothelial carcinoma-comparative clinicopathological and molecular study.

Authors:  Ljubinka Jankovic Velickovic; Zana Dolicanin; Takanori Hattori; Ivana Pesic; Biljana Djordjevic; Mariola Stojanovic; Jablan Stankovic; Milan Visnic; Vladisav Stefanovic
Journal:  Pathol Oncol Res       Date:  2010-12-02       Impact factor: 3.201

Review 2.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 3.  Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Authors:  Marie-Lisa Eich; Lars Dyrskjøt; George J Netto
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

4.  An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions.

Authors:  C Xu; X Yang; Y Wang; N Ding; R Han; Y Sun; Y Wang
Journal:  Cancer Gene Ther       Date:  2017-05-19       Impact factor: 5.987

Review 5.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 6.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

7.  Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Young-Hee Maeng; Su-Yong Eun; Jung-Sik Huh
Journal:  Korean J Urol       Date:  2010-02-18

Review 8.  Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview.

Authors:  Ming Zhao; Xiang-Lei He; Xiao-Dong Teng
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

9.  Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.

Authors:  Andres Matoso; Vamsi Parimi; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2021-04-19       Impact factor: 3.526

10.  Role of morphometry and proliferative parameters in grading of urothelial neoplasms.

Authors:  Monika Sangwan; Sunita Singh; Santosh Kumar; Sonia Chabbra; Rajeev Sen; Praveen Rana; Shivani Malik; Sonia Singh; Ramesh Lamba
Journal:  Cent European J Urol       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.